The Rise of Weight-Loss Drugs: Profits Surge as Health Systems Consider Coverage

The question of whether health systems and insurers will cover the cost of weight-loss drugs, such as "skinny jabs," is being raised. While these drugs have shown promising results in clinical trials, their high cost and potential side effects pose challenges for widespread coverage. Some argue that the long-term health benefits and potential cost savings from treating obesity-related conditions could justify coverage, while others express concerns about the ethical implications and the need for more evidence on the drugs' effectiveness.